What is the recommended dosing schedule for Strattera (atomoxetine) for children, adolescents, and adults, including adjustments for weight, CYP2D6 metabolism status, and renal impairment?

Strattera Dosing

Strattera (atomoxetine) should be initiated at 0.5 mg/kg/day in children and adolescents up to 70 kg, then increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day, with a maximum of 1.4 mg/kg/day or 100 mg/day (whichever is lower). 1

Weight-Based Dosing Algorithm

Children and Adolescents ≤70 kg

• Starting dose: 0.5 mg/kg/day (can be given as single morning dose or divided morning/late afternoon)
• Target dose: 1.2 mg/kg/day (increase after minimum 3 days)
• Maximum dose: 1.4 mg/kg/day or 100 mg/day, whichever is lower
• Dose escalation: After 2-4 additional weeks at target, may increase to maximum if response is suboptimal 1, 2

Children and Adolescents >70 kg and Adults

• Starting dose: 40 mg/day
• Target dose: 80 mg/day (increase after minimum 3 days)
• Maximum dose: 100 mg/day
• Dose escalation: After 2-4 additional weeks, may increase to 100 mg if response inadequate 1

The evidence demonstrates a clear dose-response relationship, with 1.2 mg/kg/day and 1.8 mg/kg/day showing superior efficacy compared to placebo, while 0.5 mg/kg/day showed intermediate efficacy 3. The 1.2 mg/kg/day dose is as effective as 1.8 mg/kg/day and represents the appropriate initial target for most patients 3.

Critical Dosing Adjustments

CYP2D6 Poor Metabolizers or Strong CYP2D6 Inhibitor Use

This is a crucial consideration, as approximately 7% of the population are CYP2D6 poor metabolizers with significantly higher plasma levels and longer half-lives 2.

For children/adolescents ≤70 kg:

• Starting dose: 0.5 mg/kg/day
• Target dose: 1.2 mg/kg/day ONLY if symptoms fail to improve after 4 weeks AND initial dose is well tolerated 1

For children/adolescents >70 kg and adults:

• Starting dose: 40 mg/day
• Target dose: 80 mg/day ONLY if symptoms fail to improve after 4 weeks AND initial dose is well tolerated 1

Strong CYP2D6 inhibitors include paroxetine, fluoxetine, and quinidine 2, 1. Research confirms that poor metabolizers experience markedly greater symptom reduction but also greater cardiovascular effects and adverse events including decreased appetite and tremor 4. Poor metabolizers are more likely to discontinue due to toxicity, while normal/ultrarapid metabolizers are more likely to discontinue due to lack of efficacy 5.

Hepatic Impairment

Moderate hepatic impairment (Child-Pugh Class B):

• Reduce initial and target doses to 50% of normal dose 1

Severe hepatic impairment (Child-Pugh Class C):

• Reduce initial and target doses to 25% of normal dose 1

Renal Impairment

The FDA label does not specify dose adjustments for renal impairment 1. However, atomoxetine is primarily metabolized hepatically via CYP2D6, with renal excretion playing a secondary role 2. No routine dose adjustment is required for renal impairment based on current evidence.

Administration Details

• Can be taken with or without food 1
• Can be given once daily (morning) or divided into two doses (morning and late afternoon/evening) 1
• Capsules must be swallowed whole—do not open 1
• Can be discontinued without tapering 1
• Available formulations: 10,18,25,40,60,80,100 mg capsules and 4 mg/mL oral solution 2

Duration and Monitoring

Onset of effect: Unlike stimulants with rapid onset, atomoxetine requires 6-12 weeks for full therapeutic effect 2. This delayed onset is a critical counseling point.

Maintenance therapy: The benefit of continued treatment has been demonstrated in controlled trials. Patients should be periodically reassessed to determine ongoing need, but there is no requirement for medication-free intervals as with stimulants 1.

Critical Safety Monitoring

Black Box Warning: Suicidal Ideation

All children and adolescents must be monitored closely for suicidality, clinical worsening, and unusual behavioral changes, especially during the first few months of treatment or at dose changes 2. This risk was identified in pooled analyses of 12 placebo-controlled trials and did not occur in adult trials 2.

Cardiovascular Monitoring

• Obtain personal and family cardiac history before initiation
• Monitor blood pressure and heart rate at baseline and during treatment
• Common adverse effects include nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence in children/adolescents 2

Common Pitfalls to Avoid

1. Escalating dose too rapidly in CYP2D6 poor metabolizers or those on strong inhibitors—this dramatically increases adverse effects 4, 5
2. Expecting immediate response—counsel patients that full effect takes 6-12 weeks, unlike stimulants 2
3. Not adjusting for hepatic impairment—failure to reduce dose can lead to toxicity 1
4. Opening capsules—must be swallowed whole 1
5. Forgetting to monitor for suicidality in pediatric patients—this is a black box warning requiring vigilant monitoring 2, 1